Human disease
Huntington disease
Mondo defines it as: “Huntington disease (HD) is a rare neurodegenerative disorder of the central nervous system characterized by unwanted choreatic movements, behavioral and psychiatric disturbances and dementia.”
1 disease group in OMIA reaches this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 485 | Huntington disease | Both routes | 4 | Drug |
63.2
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| HTT | 0.69 | 8,027 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Atomoxetine | None of these genes | Approved |
| Guanfacine | None of these genes | Approved |
| Lisdexamfetamine | None of these genes | Approved |
| Methylphenidate | None of these genes | Approved |
| Tetrabenazine | None of these genes | Approved |
| Creatine | None of these genes | Phase 3 |
| Dalzanemdor | None of these genes | Phase 3 |
| Latrepirdine | None of these genes | Phase 3 |
| Metformin | None of these genes | Phase 3 |
| Olanzapine | None of these genes | Phase 3 |
| Pridopidine | None of these genes | Phase 3 |
| Riluzole | None of these genes | Phase 3 |
| Tiapride | None of these genes | Phase 3 |
| Tominersen | HTT | Phase 3 |
| Ubidecarenone | None of these genes | Phase 3 |
| Votoplam | None of these genes | Phase 3 |
| Cysteamine | None of these genes | Phase 2/3 |
| Minocycline | None of these genes | Phase 2/3 |
| Acetylcysteine | None of these genes | Phase 2 |
| Amantadine | None of these genes | Phase 2 |
| Anx-005 | None of these genes | Phase 2 |
| Bevantolol | None of these genes | Phase 2 |
| Biotin | None of these genes | Phase 2 |
| Branaplam | None of these genes | Phase 2 |
| Cannabidiol | None of these genes | Phase 2 |
| Citalopram | None of these genes | Phase 2 |
| Dronabinol | None of these genes | Phase 2 |
| Epigalocatechin Gallate | None of these genes | Phase 2 |
| Fenofibrate | None of these genes | Phase 2 |
| Glycerol Phenylbutyrate | None of these genes | Phase 2 |
| Laquinimod | None of these genes | Phase 2 |
| Lithium Carbonate | None of these genes | Phase 2 |
| Mardepodect | None of these genes | Phase 2 |
| Mavoglurant | None of these genes | Phase 2 |
| Memantine | None of these genes | Phase 2 |
| Neflamapimod | None of these genes | Phase 2 |
| Pepinemab | None of these genes | Phase 2 |
| Phenylbutanoic Acid | None of these genes | Phase 2 |
| Srx246 | None of these genes | Phase 2 |
| Thiamine Ion | None of these genes | Phase 2 |
| Triheptanoin | None of these genes | Phase 2 |
| Valproic Acid | None of these genes | Phase 2 |
| Lexanersen | None of these genes | Phase 1/2 |
| Rovanersen | None of these genes | Phase 1/2 |
| Alendronic Acid | None of these genes | Phase 1 |
| Gsk-356278 | None of these genes | Phase 1 |
| Haloperidol | None of these genes | Phase 1 |
| Idebenone | None of these genes | Phase 1 |
| Nilotinib | None of these genes | Phase 1 |
| Pbf-999 | None of these genes | Phase 1 |
| Risperidone | None of these genes | Phase 1 |
| Sertraline | None of these genes | Phase 1 |
| Ursodiol | None of these genes | Phase 1 |
| Calmidazolium | None of these genes | Investigational new drug |
| Ramelteon | None of these genes | Unknown |
| Rovanersen Sodium | None of these genes | Unknown |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.